Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
J Mycol Med ; 34(3): 101490, 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38852225

ABSTRACT

Due to large outbreaks observed worldwide, Candida auris has emerged as a major threat to healthcare facilities. To prevent these phenomena, a systematic screening should be performed in patients transferred from regions where the pathogen is highly endemic. In this study, we recorded and analyzed French mycologists' current knowledge and practice regarding C. auris screening and diagnosis. Thirty-six centers answered an online questionnaire. Only 11 (30.6 %) participants were aware of any systematic screening for C. auris for patients admitted to their hospital. In the case of post-admission screening, axillae/groins (n = 21), nares (n = 7), rectum (n = 9), and mouth (n = 6) alone or various combinations were the body sites the most frequently sampled. Only six centers (8.3 %) reported using a commercially available plate allowing the differentiation of C. auris colonies from that of other Candida species, while five laboratories (13.8 %) had implemented a C. auris-specific qPCR. Considering the potential impact on infected patients and the risk of disorganization in the care of patients, it is crucial to remember to biologists and clinicians the utmost importance of systematic screening on admission.

2.
J Infect ; 84(2): 227-236, 2022 02.
Article in English | MEDLINE | ID: mdl-34838593

ABSTRACT

BACKGROUND: Cerebral aspergillosis (CA) is a life-threatening disease for which diagnosis and management remain challenging. Detailed analyses from large cohorts are lacking. METHODS: We included 119 cases of proven (n = 54) or probable (n = 65) CA diagnosed between 2006 and 2018 at 20 French hospitals. Data were collected at baseline and during follow-up. Cerebral imaging was reviewed centrally by two neuroradiologists. RESULTS: The most frequent underlying conditions were hematological malignancy (40%) and solid organ transplantation (29%). Galactomannan was detected in the serum of 64% of patients. In 75% of cases, at least one of galactomannan, Aspergillus PCR, and ß-d-glucan was positive in the cerebrospinal fluid. Six-week mortality was 45%. Two distinct patterns of disease were identified according to presumed route of dissemination. Presumed haematogenous dissemination (n = 88) was associated with a higher frequency of impaired consciousness (64%), shorter time to diagnosis, the presence of multiple abscesses (70%), microangiopathy (52%), detection of serum galactomannan (69%) and Aspergillus PCR (68%), and higher six-week mortality (54%). By contrast, contiguous dissemination from the paranasal sinuses (n = 31) was associated with a higher frequency of cranial nerve palsy (65%), evidence of meningitis on cerebral imaging (83%), macrovascular lesions (61%), delayed diagnosis, and lower six-week mortality (30%). In multivariate analysis and in a risk prediction model, haematogenous dissemination, hematological malignancy and the detection of serum galactomannan were associated with higher six-week mortality. CONCLUSION: Distinguishing between hematogenous and contiguous dissemination patterns appears to be critical in the workup for CA, as they are associated with significant differences in clinical presentation and outcome.


Subject(s)
Antifungal Agents , Aspergillosis , Antifungal Agents/therapeutic use , Aspergillosis/diagnosis , Aspergillus , Cohort Studies , Edible Grain/chemistry , Humans , Mannans/analysis
3.
Med Mycol ; 59(2): 126-138, 2021 Feb 04.
Article in English | MEDLINE | ID: mdl-32534456

ABSTRACT

Interlaboratory evaluations of Mucorales qPCR assays were developed to assess the reproducibility and performance of methods currently used. The participants comprised 12 laboratories from French university hospitals (nine of them participating in the Modimucor study) and 11 laboratories participating in the Fungal PCR Initiative. For panel 1, three sera were each spiked with DNA from three different species (Rhizomucor pusillus, Lichtheimia corymbifera, Rhizopus oryzae). For panel 2, six sera with three concentrations of R. pusillus and L. corymbifera (1, 10, and 100 genomes/ml) were prepared. Each panel included a blind negative-control serum. A form was distributed with each panel to collect results and required technical information, including DNA extraction method, sample volume used, DNA elution volume, qPCR method, qPCR template input volume, qPCR total reaction volume, qPCR platform, and qPCR reagents used. For panel 1, assessing 18 different protocols, qualitative results (positive or negative) were correct in 97% of cases (70/72). A very low interlaboratory variability in Cq values (SD = 1.89 cycles) were observed. For panel 2 assessing 26 different protocols, the detection rates were high (77-100%) for 5/6 of spiked serum. There was a significant association between the qPCR platform and performance. However, certain technical steps and optimal combinations of factors may also impact performance. The good reproducibility and performance demonstrated in this study support the use of Mucorales qPCR as part of the diagnostic strategy for mucormycosis.


Subject(s)
Clinical Laboratory Techniques/standards , DNA, Fungal/genetics , Molecular Diagnostic Techniques/standards , Mucorales/genetics , Mucormycosis/blood , Mucormycosis/diagnosis , Real-Time Polymerase Chain Reaction/standards , Clinical Laboratory Techniques/instrumentation , Clinical Laboratory Techniques/methods , France , Hospitals, University/statistics & numerical data , Humans , Observer Variation , Reproducibility of Results
4.
J Mycol Med ; 30(2): 100970, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32334948

ABSTRACT

A survey of mycology laboratories for antifungal susceptibility testing (AFST) was undertaken in France in 2018, to better understand the difference in practices between the participating centers and to identify the difficulties they may encounter as well as eventual gaps with published standards and guidelines. The survey captured information from 45 mycology laboratories in France on how they perform AFST (number of strains tested, preferred method, technical and quality aspects, interpretation of the MIC values, reading and interpretation difficulties). Results indicated that 86% of respondents used Etest as AFST method, with a combination of one to seven antifungal agents tested. Most of the participating laboratories used similar technical parameters to perform their AFST method and a large majority used, as recommended, internal and external quality assessments. Almost all the participating mycology laboratories (98%) reported difficulties to interpret the MIC values, especially when no clinical breakpoints are available. The survey highlighted that the current AFST practices in France need homogenization, particularly for MIC reading and interpretation.


Subject(s)
Antifungal Agents/therapeutic use , Laboratories , Microbial Sensitivity Tests , Mycology , Professional Practice/statistics & numerical data , Disk Diffusion Antimicrobial Tests/methods , Disk Diffusion Antimicrobial Tests/standards , Disk Diffusion Antimicrobial Tests/statistics & numerical data , Drug Resistance, Fungal , France , History, 21st Century , Humans , Laboratories/standards , Laboratories/statistics & numerical data , Laboratory Proficiency Testing/methods , Laboratory Proficiency Testing/statistics & numerical data , Microbial Sensitivity Tests/methods , Microbial Sensitivity Tests/standards , Microbial Sensitivity Tests/statistics & numerical data , Mycology/history , Mycology/methods , Mycology/standards , Mycology/statistics & numerical data , Professional Practice/standards , Quality Control , Surveys and Questionnaires
5.
J Mycol Med ; 30(2): 100967, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32321676

ABSTRACT

A 44-year-old woman, victim of a road accident in Mali was diagnosed with left knee arthritis. Joint effusion aspiration and subcutaneous surgical biopsies were positive for a melanized asexual ascomycete. Using microscopy and molecular biology, the fungus was identified as Curvularia sp. In vitro antifungal susceptibility was determined by the EUCAST broth microdilution reference technique and by E-test. The patient was treated with liposomal amphotericin B before posaconazole relay. Mycological samples obtained 10 days after starting the antifungal therapy by liposomal amphotericin B were negative in culture. Curvularia spp. are environmental fungi which can under certain conditions be pathogenic for humans.


Subject(s)
Accidents, Traffic , Arthritis, Infectious/microbiology , Ascomycota , Knee Injuries/complications , Knee Injuries/microbiology , Adult , Antifungal Agents/therapeutic use , Arthritis, Infectious/diagnosis , Arthritis, Infectious/drug therapy , Arthritis, Infectious/immunology , Ascomycota/isolation & purification , Ascomycota/physiology , Fatal Outcome , Female , France , Humans , Immunocompetence , Knee Injuries/drug therapy , Knee Injuries/immunology , Knee Joint/microbiology , Mali , Mycoses/complications , Mycoses/diagnosis , Mycoses/drug therapy , Mycoses/microbiology , Quadriplegia/etiology , Quadriplegia/microbiology , Spinal Cord Injuries/complications , Spinal Cord Injuries/microbiology , Travel-Related Illness
9.
Clin Microbiol Infect ; 26(3): 291-298, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31539634

ABSTRACT

OBJECTIVES: Neonatal invasive candidiasis (NIC) is a leading cause of infection-related morbidity and mortality in preterm neonates. Several studies have shown that (1,3)-Beta-d-glucan (BDG) was accurate in detecting invasive fungal infection in adults, but studies in neonates are scarce. The aim was to obtain summary estimates of the accuracy of BDG detection in serum for the diagnosis of NIC. METHODS: We searched Medline, Embase, Clinicaltrials.gov, and Google Scholar (inception to July 2019). We checked the reference lists of included studies, clinical guidelines, and review articles. We included studies that assessed the accuracy of BDG against a reference standard that defined groups of patients with ordinal levels of NIC probability (e.g. proven, probable, possible) and included fungal blood culture. Participants were neonates suspected of having NIC. The intervention was BDG measurement in serum (Fungitell® assay). We assessed risk of bias and applicability using QUADAS-2. We used bivariate meta-analysis to produce summary estimates of diagnostic accuracy at prespecified positivity thresholds of 80 and 120 pg/mL. This study was registered with PROSPERO (CRD42018089545). RESULTS: We included eight studies (465 participants). Of these, two were judged at low overall risk of bias. There was substantial variability across studies in the reference standards used. At a positivity threshold of 80 pg/mL, summary estimates of sensitivity and specificity of BDG were 89% (95% CI: 80-94%) and 60% (53-66%), respectively; summary sensitivity for detecting proven cases of NIC was 99% (93-100%). At a positivity threshold of 120 pg/mL, summary estimates of sensitivity and specificity were 81% (71-88%) and 80% (67-88%), respectively. CONCLUSIONS: Because of high sensitivity, BDG seems promising to rule-out NIC. It might be too early to recommend its use because of the scarcity of reliable clinical data, heterogeneity in case definitions, and unstable accuracy estimates.


Subject(s)
Biomarkers , Candidiasis, Invasive/blood , Candidiasis, Invasive/diagnosis , beta-Glucans/blood , Age Factors , Candidiasis, Invasive/microbiology , Humans , Infant, Newborn , Proteoglycans , ROC Curve , Reproducibility of Results , Sensitivity and Specificity
10.
Article in English | MEDLINE | ID: mdl-31844011

ABSTRACT

Reference methods used to assess the drug susceptibilities of Aspergillus fumigatus isolates consisted of EUCAST and CLSI standardized broth microdilution techniques. Considering the increasing rate and the potential impact on the clinical outcome of azole resistance in A. fumigatus, more suitable techniques for routine testing are needed. The gradient concentration strip (GCS) method has been favorably evaluated for yeast testing. The aim of this study was to compare the CGS test with EUCAST broth microdilution for amphotericin B (AMB), posaconazole (PCZ), itraconazole (ITZ), voriconazole (VRZ), and isavuconazole (ISA). A total of 121 Aspergillus section Fumigati strains were collected, including 24 A. fumigatus sensu stricto strains that were resistant to at least one azole drug. MICs were determined using GCS and EUCAST methods. Essential agreement between the 2 methods was considered when MICs fell within ±1 dilution or ±2 dilutions of the 2-fold dilution scale. Categorical agreement was defined as the percentage of strains classified in the same category (susceptible, intermediate, or resistant) with both methods. Essential agreements with ±1 dilution and ±2 dilutions were 96.7, 93.4, 90.0, 89.3, and 95% and 100, 99.2, 100, 97.5, and 100% for AMB, PCZ, ITZ, VRZ, and ISA, respectively. Categorical agreements were 94.3, 86.1, 89.3, and 88.5% for AMB, PCZ, ITZ, and VRZ, respectively. Detection of resistance was missed with the GCS for one strain (4.1%) for PCZ and for 2 strains (8.3%) for ISA. Determination of ITZ MICs using the GCS allowed the detection of 91.7% of azole-resistant strains. The GCS test appears to be a valuable method for screening azole-resistant A. fumigatus clinical isolates.


Subject(s)
Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Azoles/pharmacology , Aspergillus/drug effects , Aspergillus/genetics , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Itraconazole/pharmacology , Microbial Sensitivity Tests , Nitriles/pharmacology , Pyridines/pharmacology , Triazoles/pharmacology , Voriconazole/pharmacology
12.
J Mycol Med ; 27(4): 449-456, 2017 Dec.
Article in French | MEDLINE | ID: mdl-29132793

ABSTRACT

The increase use of immunosuppressive treatments in patients with solid cancer and/or inflammatory diseases requires revisiting our practices for the prevention of infectious risk in the care setting. A review of the literature by a multidisciplinary working group at the beginning of 2014 wished to answer the following 4 questions to improve healthcare immunocompromised patients: (I) How can we define immunocompromised patients with high, intermediate and low infectious risk, (II) which air treatment should be recommended for this specific population? (III) What additional precautions should be recommended for immunocompromised patients at risk for infection? (IV) Which global environmental control should be recommended? Based on data from the literature and using the GRADE method, we propose 15 recommendations that could help to reduce the risk of infection in these exposed populations.


Subject(s)
Immunocompromised Host , Infection Control , Infections , Air Microbiology , Disease Susceptibility , France , Humans , Practice Guidelines as Topic , Risk Factors
13.
Int J Antimicrob Agents ; 50(1): 81-87, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28499958

ABSTRACT

Imipenem is active against extended-spectrum ß-lactamase-producing Enterobacteriaceae (ESBL-E) but favours the intestinal emergence of resistance. The effects of imipenem on intestinal microbiota have been studied using culture-based techniques. In this study, the effects were investigated in patients using culture and metagenomic techniques. Seventeen hospitalised adults receiving imipenem were included in a multicentre study (NCT01703299, http://www.clinicaltrials.gov). Most patients had a history of antibiotic use and/or hospitalisation. Stools were collected before, during and after imipenem treatment. Bacterial and fungal colonisation was assessed by culture, and microbiota changes were assessed using metagenomics. Unexpectedly, high colonisation rates by imipenem-susceptible ESBL-E before treatment (70.6%) remained stable over time, suggesting that imipenem intestinal concentrations were very low. Carriage rates of carbapenem-resistant Gram-negative bacilli (0-25.0%) were also stable over time, whereas those of yeasts (64.7% before treatment) peaked at 76.5% during treatment and decreased thereafter. However, these trends were not statistically significant. Yeasts included highly diverse colonising Candida spp. Metagenomics showed no global effect of imipenem on the bacterial taxonomic profiles at the sequencing depth used but demonstrated specific changes in the microbiota not detected with culture, attributed to factors other than imipenem, including sampling site or treatment with other antibiotics. In conclusion, culture and metagenomics were highly complementary in characterising the faecal microbiota of patients. The changes observed during imipenem treatment were unexpectedly limited, possibly because the microbiota was already disturbed by previous antibiotic exposure or hospitalisation.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Carrier State/microbiology , Enterobacteriaceae/isolation & purification , Feces/microbiology , Imipenem/therapeutic use , Inpatients , beta-Lactamases/analysis , Adult , Aged , Aged, 80 and over , Bacteriological Techniques , Enterobacteriaceae/enzymology , Enterobacteriaceae/genetics , Female , Humans , Male , Metagenomics , Middle Aged , beta-Lactamases/genetics
14.
Mucosal Immunol ; 10(5): 1335-1350, 2017 09.
Article in English | MEDLINE | ID: mdl-28176789

ABSTRACT

The host immune status is critical for preventing opportunistic infections with Candida albicans. Whether the natural fungal diversity that exists between C. albicans isolates also influences disease development remains unclear. Here, we used an experimental model of oral infection to probe the host response to diverse C. albicans isolates in vivo and found dramatic differences in their ability to persist in the oral mucosa, which inversely correlated with the degree and kinetics of immune activation in the host. Strikingly, the requirement of interleukin (IL)-17 signaling for fungal control was conserved between isolates, including isolates with delayed induction of IL-17. This underscores the relevance of IL-17 immunity in mucosal defense against C. albicans. In contrast, the accumulation of neutrophils and induction of inflammation in the infected tissue was strictly strain dependent. The dichotomy of the inflammatory neutrophil response was linked to the capacity of fungal strains to cause cellular damage and release of alarmins from the epithelium. The epithelium thus translates differences in the fungus into qualitatively distinct host responses. Altogether, this study provides a comprehensive understanding of the antifungal response in the oral mucosa and demonstrates the relevance of evaluating intraspecies differences for the outcome of fungal-host interactions in vivo.


Subject(s)
Alarmins/immunology , Bacterial Proteins/immunology , Candida albicans/physiology , Candidiasis/microbiology , Keratinocytes/physiology , Mouth Mucosa/immunology , Neutrophils/immunology , Biodiversity , Candida albicans/pathogenicity , Cell Line , Cell Movement , Host-Pathogen Interactions , Humans , Immunity, Mucosal , Interleukin-17/metabolism , Keratinocytes/microbiology , Mouth Mucosa/microbiology , Signal Transduction , Species Specificity , Symbiosis , Virulence
15.
Am J Infect Control ; 45(1): 39-41, 2017 01 01.
Article in English | MEDLINE | ID: mdl-27665035

ABSTRACT

BACKGROUND: Aspergillus fumigatus is a major opportunistic pathogen causing nosocomial infection. Hospital outbreaks of invasive aspergillosis have been associated with demolition and building construction. This study was designed to examine the impact of meteorologic factors and different periods of work on outdoor fungal airborne concentrations. METHODS: The study was conducted at Necker Enfants Malades Hospital, a 650-bed teaching care hospital recently involved in a large construction program, including renovation, construction, and demolition. During the work phases, prospective external air samplings were performed 3 times a week, and meteorologic parameters were collected every day. RESULTS: Two hundred and one samples were collected. Aspergillus spp were found in 80.1% of samples, with a median concentration of 16 colony forming units (CFU)/m3. A significant increase in the colony count of molds occurred after demolition. In the multivariate analysis, factors associated with overall fungi concentration were the type of work construction and temperature. Elevated Aspergillus spp concentrations (>20 CFU/m3) were associated with higher temperature. CONCLUSIONS: Our findings underline the importance of environmental surveillance. According to our results we suggest that demolition work should be performed during the winter and fall seasons.


Subject(s)
Air Microbiology , Aspergillus fumigatus/isolation & purification , Environmental Monitoring/methods , Hospital Design and Construction , Aspergillosis/prevention & control , France , Hospitals, Teaching , Humans , Infection Control/methods , Prospective Studies
16.
J Mycol Med ; 26(4): 385-390, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27887809

ABSTRACT

OBJECTIVE OF THE STUDY: An estimation of burden of serious fungal diseases in France is essential data to inform public health priorities on the importance of resources and research needed on these infections. In France, precise data are available for invasive fungal diseases but estimates for several other diseases such as chronic and immunoallergic diseases are by contrast less known. MATERIALS AND METHODS: A systematic literature search was conducted using the Web of Science Platform. Published epidemiology papers reporting fungal infection rates from France were identified. Where no data existed, we used specific populations at risk and fungal infection frequencies in those populations to estimate national incidence or prevalence, depending on the condition. RESULTS: The model predicts high prevalences of severe asthma with fungal sensitization episodes (189 cases/100,000 adults per year), of allergic bronchopulmonary aspergillosis (145/100,000) and of chronic pulmonary aspergillosis (5.24/100,000). Besides, estimated incidence for invasive aspergillosis is 1.8/100,000 annually based on classical high risk factors. Estimates for invasive mucormycosis, pneumocystosis and cryptococcosis are 0.12/100,000, 1/100,000 and 0.2/100,000, respectively. Regarding invasive candidiasis, more than 10,000 cases per year are estimated, and a much higher number of recurrent vaginal candidiasis is probable but must be confirmed. Finally, this survey was an opportunity to report a first picture of the frequency of tinea capitis in France. CONCLUSION: Using local and literature data of the incidence or prevalence of fungal infections, approximately 1,000,000 (1.47%) people in France are estimated to suffer from serious fungal infections each year.


Subject(s)
Mycoses/epidemiology , France/epidemiology , Humans , Incidence , Mycoses/microbiology , Mycoses/pathology , Prevalence , Severity of Illness Index
17.
Antimicrob Agents Chemother ; 60(8): 5088-91, 2016 08.
Article in English | MEDLINE | ID: mdl-27297480

ABSTRACT

In vitro susceptibility of 933 Candida isolates, from 16 French hospitals, to micafungin was determined using the Etest in each center. All isolates were then sent to a single center for determination of MICs by the EUCAST reference method. Overall essential agreement between the two tests was 98.5% at ±2 log2 dilutions and 90.2% at ±1 log2 dilutions. Categorical agreement was 98.2%. The Etest is a valuable alternative to EUCAST for the routine determination of micafungin MICs in medical mycology laboratories.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Echinocandins/pharmacology , Lipopeptides/pharmacology , Candida/genetics , Drug Resistance, Fungal/genetics , Micafungin , Microbial Sensitivity Tests
18.
Clin Microbiol Infect ; 22(5): 434-7, 2016 May.
Article in English | MEDLINE | ID: mdl-26802213

ABSTRACT

Aspergillus spp. invasive external otitis (IEO) is a rare infection. We performed a seven-year, single-centre retrospective study from 2007 to 2014 including all patients with proven Aspergillus spp. IEO. Twelve patients were identified. All patients had a poorly controlled diabetes mellitus and one underwent solid organ transplant. The most frequently isolated species was Aspergillus flavus (n = 10) and voriconazole was the first-line therapy in all cases, with a median length of treatment of 338.5 days (158-804 days). None of the patients underwent extensive surgery. The clinical outcome was excellent. However, otological sequelae were reported, including hearing impairment (n = 7) and facial palsy (n = 3).


Subject(s)
Aspergillosis/diagnosis , Aspergillosis/pathology , Aspergillus/isolation & purification , Necrosis/pathology , Otitis Externa/diagnosis , Otitis Externa/pathology , Adult , Aged , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/microbiology , Aspergillus/classification , Diabetes Complications , Female , Humans , Male , Middle Aged , Organ Transplantation/adverse effects , Otitis Externa/drug therapy , Otitis Externa/microbiology , Retrospective Studies , Treatment Outcome , Voriconazole/therapeutic use
19.
Med Mal Infect ; 45(6): 189-98, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26026226

ABSTRACT

Invasive aspergillosis (IA) is a major cause of morbidity and mortality in immunocompromised adults and children, the number of which has been continuously increasing in the last decades. The purpose of our review was to provide epidemiological, clinical, and biological data and antifungal treatment options in the pediatric population. Several biological assays (galactomannan enzyme immunoassay, ß-D-glucan, detection of Aspergillus spp. DNA) have proven useful adjuncts for the diagnosis of IA in adult studies. However, data on these assays in children is limited by small sample sizes and sometimes conflicting results concerning their sensitivity/specificity. Pediatric treatment recommendations are mainly extrapolated from results of clinical trials performed in adults. It is thus necessary to develop new antifungal formulations specifically adapted to the pediatric population and to evaluate their pharmacokinetic/pharmacodynamic profile, their safety, and their effectiveness in infants and children.


Subject(s)
Aspergillosis , Fungemia , Adolescent , Antifungal Agents/therapeutic use , Antigens, Fungal/blood , Antineoplastic Agents/adverse effects , Aspergillosis/diagnosis , Aspergillosis/drug therapy , Aspergillosis/epidemiology , Aspergillosis/prevention & control , Aspergillus/drug effects , Aspergillus/immunology , Aspergillus/isolation & purification , Child , Child, Preschool , DNA, Fungal/blood , Fungemia/diagnosis , Fungemia/drug therapy , Fungemia/epidemiology , Fungemia/prevention & control , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Infant , Neoplasms/complications , Neoplasms/drug therapy , Postoperative Complications/drug therapy , Postoperative Complications/microbiology , Practice Guidelines as Topic , Prognosis , Randomized Controlled Trials as Topic , Risk Factors
20.
Am J Transplant ; 15(2): 560-4, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25611999

ABSTRACT

In solid organ transplant recipients, immune reconstitution inflammatory syndrome (IRIS) is a rare complication of cryptococcosis, which may require steroids in its most severe forms. Here, we report the case of a renal transplant recipient who developed severe cryptococcal meningitis-associated IRIS 1 week after immunosuppression reduction. High-dose steroids failed to improve the disease. Finally, a recombinant human monoclonal tumor necrosis factor-α (TNF-α) antagonist, adalimumab, was prescribed, and the patient rapidly experienced dramatic neurological improvement. No IRIS relapse occurred within 14 months following adalimumab discontinuation.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Cryptococcosis/complications , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/etiology , Kidney Transplantation , Severity of Illness Index , Transplant Recipients , Adalimumab , Adult , Anti-Inflammatory Agents/therapeutic use , Brain/pathology , Female , Humans , Immunosuppressive Agents , Magnetic Resonance Imaging , Meningitis, Cryptococcal/drug therapy , Meningitis, Cryptococcal/etiology , Meningitis, Cryptococcal/pathology , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...